Menezes Michelle Santos, Valença-Feitosa Fernanda, Góes Aline Santana, Santos Millena Rakel Dos, Silva Laila Santana, Santos Sylmara Nayara Pereira Dos, Lyra Divaldo Pereira de, de Oliveira Filho Alfredo Dias
Laboratory of Teaching and Research in Social Pharmacy (LEPFS), Department of Pharmacy, Federal University of Sergipe, Av. Marcelo Déda Chagas, São Cristóvão, Sergipe, Brazil.
Explor Res Clin Soc Pharm. 2024 Dec 12;17:100551. doi: 10.1016/j.rcsop.2024.100551. eCollection 2025 Mar.
To identify new drugs that present an increased risk of causing significant damage to critically ill patients due to failure in the administration process.
The systematic literature review was conducted in the PubMed, Lilacs, Scopus, Web of Science and gray literature. The year in which the study was conducted was not restricted.
The initial search in the databases identified 1477 studies. Fifty manuscripts were selected for evaluation of the full text, at the end of which seven articles were included in this systematic review. As for the characteristic of medication errors, the highest frequency occurred in the administration and prescription phases. In all included studies, incidents with drugs that led to damage were observed. The drugs that are not included in the official lists as High Alert Medications (HAM) that presented an increased risk of causing damage due to medication errors found were: risperidone and piperacycline + tazobactan, in addition to the Infectious Agent class.
The results revealed that in fact there are drugs not listed as HAM that, when used in errors, promote greater risks of generating damage in critically ill patients. These described drugs should be considered for inclusion in future official lists of HAM.
识别因给药过程失误而对重症患者造成严重损害风险增加的新药。
在PubMed、Lilacs、Scopus、Web of Science和灰色文献中进行系统的文献综述。研究开展年份不受限制。
在数据库中的初步检索识别出1477项研究。筛选出50篇手稿进行全文评估，最终7篇文章纳入本系统综述。至于用药错误的特征，最高频率出现在给药和处方阶段。在所有纳入研究中，均观察到药物导致损害的事件。未被官方列为高警示药物（HAM）但因用药错误导致损害风险增加的药物有：利培酮和哌拉西林+他唑巴坦，此外还有感染因子类。
结果显示，实际上存在未列为HAM的药物，使用失误时会增加重症患者产生损害的风险。应考虑将这些所述药物纳入未来的官方HAM清单。
